NCT07745361 — Castration-Resistant Prostate Cancer (CRPC) trial site landscape

Public-registry site landscape for NCT07745361, “Study of Oral MRT-2359 With Apalutamide in Prostate Cancer”, a Castration-Resistant Prostate Cancer (CRPC) study sponsored by Monte Rosa Therapeutics, Inc. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07745361 (registry record)
Study title	Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Official title	MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer
Sponsor	Monte Rosa Therapeutics, Inc
Condition(s)	Castration-Resistant Prostate Cancer (CRPC); Castration-Resistant Prostate Cancer; Prostate Cancer; Prostate Cancer (Adenocarcinoma)
Phase	PHASE2
Listed sites	14
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT07745361.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07745361 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →